J&J test tracks success of prostate cancer chemotherapy

02/10/2009 | Reuters

A test called CellSearch outperformed other standard tests in monitoring chemotherapy response in patients with metastasized prostate cancer, researchers found. Developed by Johnson & Johnson unit Veridex, CellSearch works by counting the number of circulating tumor cells instead of tracking levels of prostate-specific antigen, as done in conventional tests. The findings suggest that CTC counts may aid prognosis and help doctors understand whether the treatment is working, one of the study authors said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations